The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies

Human Genomics

Volumn 10, Issue 1, 2016, Pages

  Patterson, Sara E ^a   Liu, Rangjiao ^a   Statz, Cara M ^a   Durkin, Daniel ^a   Lakshminarayana, Anuradha ^a   Mockus, Susan M ^a  

^a JACKSON LABORATORY   (United States)

Author keywords

Actionability; Cancer; Clinical trials; Curation; Precision medicine

Indexed keywords

CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DATA BASE; HUMAN; LANDSCAPE; ONCOLOGY; CLINICAL TRIAL (TOPIC); DNA SEQUENCE; GENETICS; GENOMICS; KNOWLEDGE BASE; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; PATHOLOGY; PATIENT; PERSONALIZED MEDICINE; PROCEDURES;

TUMOR PROTEIN;

CLINICAL DECISION-MAKING; CLINICAL TRIALS AS TOPIC; GENOMICS; HUMANS; KNOWLEDGE BASES; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; PATIENTS; PRECISION MEDICINE; SEQUENCE ANALYSIS, DNA;

EID: 84954349452     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/s40246-016-0061-7     Document Type: Article

References (24)

1. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805-811.
2. My Cancer Genome. Vanderbilt-Ingram Cancer Center. http://www. mycancergenome.org. Accessed 20 Oct 2015.
3. Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Genenames.org: the HGNC resources in. Nucleic Acids Res 2015. 2015;43(Database issue):D1079-1085.
4. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000;15:7-12.
5. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014;32:644-52.
6. Ananda G, Mockus S, Lundquist M, Spotlow V, Simons A, Mitchell T, et al. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. Exp Mol Pathol. 2015;98:106-12.
7. Schriml LM, Mitraka E. The Disease Ontology: fostering interoperability between biological and clinical human disease-related data. Mamm Genome Off J Int Mamm Genome Soc. 2015;26:584-9.
8. Mockus S, Patterson S, Statz C, Bult C, Tsongalis G. Clinical trials in precision oncology. Clin Chem. 2015.247437. [Epub ahead of print]
9. Roper N, Stensland KD, Hendricks R, Galsky MD. The landscape of precision cancer medicine clinical trials in the United States. Cancer Treat Rev. 2015;41:385-90.
10. Di Maio S, Yip S, Al Zhrani GA, Alotaibi FE, Al Turki A, Kong E, et al. Novel targeted therapies in chordoma: an update. Ther Clin Risk Manag. 2015;11:873-83.
11. Ramakrishna R, Rostomily R, Sekhar L, Rockhill J, Ferreira M. Hemangiopericytoma: radical resection remains the cornerstone of therapy. J Clin Neurosci Off J Neurosurg Soc Australas. 2014;21:612-5.
12. Sana M, Malik HJ. Current and emerging breast cancer biomarkers. J Cancer Res Ther. 2015;11:508-13.
13. Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. OncoTargets Ther. 2015;8:157-68.
14. Kuan F-C, Kuo L-T, Chen M-C, Yang C-T, Shi C-S, Teng D, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer. 2015;113(10):1519-28.
15. Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015; 121(18):3212-20.
16. Yasuda H, Park E, Yun C-H, Sng NJ, Lucena-Araujo AR, Yeo W-L, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5:216ra177.
17. Choi YJ, Kim SY, So KS, Baek I-J, Kim WS, Choi SH, et al. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PloS One. 2015;10:e0119832.
18. Brown GR, Hem V, Katz KS, Ovetsky M, Wallin C, Ermolaeva O, et al. Gene: a gene-centered information resource at NCBI. Nucleic Acids Res. 2015; 43(Database issue):D36-42.
19. Petri V, Jayaraman P, Tutaj M, Hayman GT, Smith JR, De Pons J, et al. The pathway ontology-updates and applications. J Biomed Semant. 2014;5:7.
20. Costa DB, Nguyen K-SH, Cho BC, Sequist LV, Jackman DM, Riely GJ, et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:7060-7.
21. Robinson KW, Sandler AB. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. The Oncologist. 2013;18:115-22.
22. Turke AB, Zejnullahu K, Wu Y-L, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77-88.
23. Mancini M, Yarden Y. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Semin Cell Dev Biol. 2015;pii: S1084-9521(15)00178-0. [Epub ahead of print].
24. Gymnopoulos M, Elsliger M-A, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A. 2007;104:5569-74.